Press/Media
- 19 results
Search results
-
Rep. Castor Issues Statement Honoring 175 Inventors Inducted As 2020 Fellows of The National Academy of Inventors
Robert Desnick, Edward Schuchman & E. Premkumar Reddy
26/06/21
1 item of Media coverage
Press/Media
-
Startup Spotlight: New biopharma targets rare diseases with $35M in backing from NovaQuest
3/05/21
1 item of Media coverage
Press/Media
-
Focused On Rare Illnesses, NC Startup Aceragen Goes After Farber Disease
2/05/21
1 item of Media coverage
Press/Media
-
Fifth Annual Mount Sinai Innovation Awards
Emily Bernstein,, Calogera Simonaro, Joseph Rothstein, Li Shen, Laurie Keefer, Weiva Sieh, Dirk Hubmacher,, Edward Schuchman, Jordyn Feingold, Daniel Ranti, Chiara Vardabasso, Roberto Sanchez, Barbara Murphy, Anthony Costa, Ksenia Gorbenko, Steven Coca, Laurie Margolies, Alejandro Berenstein,, Richard Rosen & Avnish Deobhakta,
25/11/19
1 item of Media coverage
Press/Media
-
Researchers Work to Repurpose Drug to Battle Rare MPS Diseases
Calogera Simonaro & Edward Schuchman
22/01/19
1 item of Media coverage
Press/Media
-
Researchers Work to Repurpose Drug to Battle Rare MPS Diseases
Calogera Simonaro & Edward Schuchman
22/01/19
1 item of Media coverage
Press/Media
-
Mount Sinai joins with Paradigm and ReqMed to repurpose drug for treatment of MPS
Calogera Simonaro & Edward Schuchman
21/01/19
1 item of Media coverage
Press/Media
-
Mount Sinai Partners with Paradigm Biopharmaceuticals Ltd. and ReqMed Company, Ltd. to Repurpose Drug to Battle Rare MPS Diseases
Calogera Simonaro & Edward Schuchman
20/01/19
1 item of Media coverage
Press/Media
-
Mount Sinai Partners with Paradigm Biopharmaceuticals Ltd. and ReqMed Company, Ltd. to Repurpose Drug to Battle Rare MPS Diseases [Sudan Tribune]
Calogera Simonaro & Edward Schuchman
19/01/19
1 item of Media coverage
Press/Media
-
Mount Sinai Partners with Paradigm Biopharmaceuticals Ltd. and ReqMed Company, Ltd. to Repurpose Drug to Battle Rare MPS Diseases
Calogera Simonaro & Edward Schuchman
18/01/19
5 items of Media coverage
Press/Media
-
Mount Sinai Partners with Paradigm Biopharmaceuticals Ltd. and ReqMed Company, Ltd. to Repurpose Drug to Battle Rare MPS Diseases; The Icahn School of Medicine at Mount Sinai has entered into two exclusive licenses to develop the drug pentosan polysulfate
Calogera Simonaro & Edward Schuchman
18/01/19
2 items of Media coverage
Press/Media
-
Mount Sinai Partners with Paradigm Biopharmaceuticals Ltd. and ReqMed...
Calogera Simonaro & Edward Schuchman
18/01/19
3 items of Media coverage
Press/Media
-
Mount Sinai Partners with Paradigm Biopharmaceuticals Ltd. and ReqMed Company, Ltd. to Repurpose Drug to Battle Rare MPS Diseases; The Icahn School of Medicine at Mount Sinai has entered into two exclusive licenses to develop the drug pentosan polysulfate
Calogera Simonaro & Edward Schuchman
18/01/19
1 item of Media coverage
Press/Media
-
Mount Sinai Partners with Paradigm Biopharmaceuticals Ltd. and ReqMed Company, Ltd. to Repurpose Drug to Battle Rare MPS Diseases
Calogera Simonaro & Edward Schuchman
18/01/19
1 item of Media coverage
Press/Media
-
Mount Sinai Partners with Paradigm Biopharmaceuticals Ltd. and ReqMed Company, Ltd. to Repurpose Drug to Battle Rare MPS Diseases.
Calogera Simonaro & Edward Schuchman
18/01/19
1 item of Media coverage
Press/Media
-
Mount Sinai Partners With Paradigm Biopharmaceuticals Ltd., ReqMed Company, Ltd. to Repurpose Drug to Battle Rare MPS Diseases
Calogera Simonaro & Edward Schuchman
18/01/19
1 item of Media coverage
Press/Media
-
Mount Sinai Partners with Paradigm Biopharmaceuticals Ltd. and ReqMed Company, Ltd. to Repurpose Drug to Battle Rare MPS Diseases
Calogera Simonaro & Edward Schuchman
18/01/19
6 items of Media coverage
Press/Media